Open AccessLong-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Author(s) -
Floyd R. Sallee,
A. G. Lyne,
Timothy Wigal,
James J. McGough
Publication year - 2009
Publication title -
journal of child and adolescent psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 84
eISSN - 1557-8992
pISSN - 1044-5463
DOI - 10.1089/cap.2008.0080
Subject(s) - guanfacine , attention deficit hyperactivity disorder , adverse effect , attention deficit , medicine , extended release , safety profile , pediatrics , psychiatry , pharmacology , anesthesia , clonidine
Short-term, controlled studies of extended-release guanfacine (GXR), a selective alpha(2A)-adrenoreceptor agonist, demonstrate efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms as monotherapy. This 2-year open-label study was conducted to further assess the long-term safety and efficacy of GXR.